乳腺癌合并2型糖尿病患者沉默信息调节因子1表达及其意义

 【摘要】　目的　研究沉默信息调节因子1（SIRT1）在乳腺癌合并2型糖尿病中的表达，分析其与乳腺癌合并2型糖尿病患者相关临床病理指标之间的关系。方法　应用免疫组织化学方法检测30例乳腺癌合并2型糖尿病患者、65例非糖尿病乳腺癌患者的乳腺癌组织和18例正常乳腺组织中SIRT1的表达情况。结果　SIRT1在非糖尿病、合并2型糖尿病乳腺癌组织和正常乳腺组织中的表达率分别为76.9 %（50／65）、50.0 %（15／30）、5.6 %（1／18），乳腺癌组织均高于正常乳腺组织（χ2＝24.618，P＝0.000），合并2型糖尿病者SIRT1的表达率低于非糖尿病患者（χ2＝6.886，P＝0.009）。合并2型糖尿病的乳腺癌患者SIRT1的表达与淋巴结转移（P＝0.011）、pTNM分期（P＝0.028）、p53蛋白的表达（P＝0.003）以及Her-2的表达（P＝0.031）均呈正相关。结论　SIRT1在乳腺癌合并2型糖尿病患者乳腺癌组织中过表达，但阳性表达率低于未合并糖尿病乳腺癌组，其可能是影响糖尿病病程进展的重要分子； SIRT1的表达与多项临床病理指标有关，可能成为判断合并2型糖尿病乳腺癌恶性程度及评估预后的生物学指标。

Significance of SIRT1 expression in breast cancer

Objective To investigate the expression of SIRT1 and its association with clinicopathologic features in breast carcinoma with type 2 diabetes mellitus. Methods The expression of SIRT1 in 30 breast cancer with type 2 diabetes mellitus, 65 samples of breast cancer without diabetes mellitus and 18 samples of corresponding normal breast tissues was investigated using immunohistochemistry.Results The positive rate of SIRT1 in breast cancer tissues was significantly higher than that breast cancer with type 2 diabetes mellitus and normal breast tissue (P ＜0.05). In breast cancer with type 2 diabetes mellitus group. The positive rate of SIRT1 was significantly higher than that normal breast tissue (P ＜0.05). The expression of SIRT1 was positively correlated with the number of lymph node (P =0.011), pTNM tumor stage (P =0.028), p53 (P =0.003) and Her-2 (P =0.031) in breast cancer with type 2 diabetes mellitus group. The expression level of SIRT1 in lymph node-positive group was higher than that in lymph node-negative group (P ＜0.05). The expression level of SIRT1 was in lymph node-positive group was higher than that in lymph node-negative group (P ＜0.05). Conclusion SIRTI was up-regulated in breast cancer with type 2 diabetes mellitus, but its expression was lower than that breast cancer without diabetes mellitus, and was associated with the progression of diabetes mellitus. SIRT1 was positively correlated with lymph node, pTNM tumor stage,p53 and Her-2, SIRT1 may be a novel biological parameter to evaluate the malignant degree of breast carcinoma and to predict prognosis of breast cancer.